Drug profile · INN
suzetrigine
JOURNAVX
suzetrigine (JOURNAVX) is an FDA-listed pharmaceutical active ingredient. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
Drug details — suzetrigine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 8
- Data quality
- 0.89
Quick answer
suzetrigine (JOURNAVX) is an FDA-listed pharmaceutical active ingredient. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Lilly buys 4E in non-opioid pain push: what investors should watch
Eli Lilly is buying 4E Therapeutics, adding another non-opioid pain pipeline to its portfolio after the SiteOne transaction. The move comes as Journavx (suzetrigine) advances in the market and in multiple clinical trials.
FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
The FDA approved Vertex Pharmaceuticals’ Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults. The decision creates a new non-opioid catalyst to track for BD teams, investors, and analysts.
FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx
The FDA approved Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults, including postoperative pain. The decision gives Vertex the first non-opioid analgesic in this setting and creates a new catalyst set for BD teams, investors, and analysts.
Vertex launches Journavx after FDA approval for acute pain
Vertex’s Journavx (suzetrigine) became the first FDA-approved non-opioid analgesic for moderate to severe acute pain on January 30, 2025. This plan frames the catalyst, label, and upcoming clinical milestones for BD teams, investors, and analysts.
Pipeline programs
Related patents
Frequently asked questions
What is suzetrigine?
suzetrigine (JOURNAVX) is an FDA-listed pharmaceutical active ingredient. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for suzetrigine?
JOURNAVX is a marketed brand name for suzetrigine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of suzetrigine?
suzetrigine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.